Danoprevir

Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC50 of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC50 higher than 10 μM) . Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC50s=0.2-0.4 nM) as well as 2b and 3a (IC50s=1.6, 3.5 nM) [1][2]. Danoprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 0.05 μM[3].

Product Specifications

CAS Number

[850876-88-9]

Product Name Alternative

ITMN-191; R7227; RO5190591; RG7227

UNSPSC

12352005

Hazard Statement

H302

Target

HCV; HCV Protease; SARS-CoV

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

COVID-19-anti-virus

Field of Research

Infection

Assay Protocol

https://www.medchemexpress.com/Danoprevir.html

Concentration

10mM

Purity

99.67

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=S(NC([C@@]1(NC([C@]2([H])C[C@@H](OC(N3CC4=C(C3)C=CC=C4F)=O)CN2C5=O)=O)C[C@]1(/C=C/CCCCC[C@@H]5NC(OC(C)(C)C)=O)[H])=O)(C6CC6)=O

Molecular Formula

C35H46FN5O9S

Molecular Weight

731.83

Precautions

H302

References & Citations

[1]Imhof I, et al. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191) .Hepatology. 2011 Apr;53 (4) :1090-9.|[2]Seiwert, Scott D., et al. Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227) . Antimicrobial Agents and Chemotherapy (2008), 52 (12), 4432-4441.|[3]Bartels DJ, et al. Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naive subjects. J Infect Dis. 2008 Sep 15;198 (6) :800-7.|[4]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6 (1) :212.